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an economic perspective, vaccination with these coverage
levels is cost-beneﬁcial.
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OBJECTIVES: To determine the annual incidence of
severe sepsis in the Netherlands by performing a point-
prevalence survey in multiple intensive care units.
METHODS: ICU’s were invited to participate in a one-
day survey and monitor patients during the ﬁrst 24 hours
of their stay, if they were admitted with a proven/
suspected infection. Patient-speciﬁc questionnaires cap-
tured demographic and clinical information, presence of
Systemic Inﬂammatory Response Syndrome (SIRS), and
the functional status of seven organ systems. The annual
national incidence was calculated from the results of the
survey following two approaches: 1) by multiplying the
survey incidence (patients/day) with the number of days
per year, corrected for the fact that the survey was held
on a weekday, and 2) by using the relation P = I ·D (P for
prevalence, I for incidence and D for duration of stay) in
which P was known from the survey and D was estimated
as the geometrical mean of duration-to-date. RESULTS:
Forty-seven ICU’s participated (in 43 general and 4 
university hospitals), representing 42% of the national
admission capacity. During the study-period, 18 patients
meeting criteria for severe sepsis were newly admitted,
and another 116 patients with severe sepsis were already
present. According to the ﬁrst calculation method, the
annual incidence of severe sepsis was 13,137 ± 2,821
patients, whereas the second method, with an estimated
D of 13.3 ± 1.1 days, lead to a calculated incidence of
8,643 ± 929 patients/year. CONCLUSIONS: Using 
the results from a point-prevalence survey, different
approaches lead to different outcomes. Both approaches
hold advantages and disadvantages. The second method
is considered superior because it is based on a larger 
population and is less sensitive to daily variations.
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OBJECTIVES: HPV DNA has been detected in up to
99.7% of all cervical cancers, and infection with 2 types
(HPV-16, 18) accounts for more than 50% of cases. 
We developed a computer-based Markov model of the
natural history of HPV infection and cervical carcino-
genesis to project the impact of a prophylactic vaccine
against HPV 16/18 infection on the age-speciﬁc incidence
and lifetime risk of invasive cervical cancer, precursor 
cervical lesions, and type-speciﬁc infection with HPV.
METHODS: A comprehensive literature review was con-
ducted to deﬁne plausible ranges for parameter values and
the model was then calibrated to the best available 
population-based data. We explored the impact of alter-
native assumptions about vaccine efﬁcacy, waning immu-
nity, and competing risks associated with non-16/18 HPV
types in vaccinated women. RESULTS: The model pre-
dicted a peak age-speciﬁc cancer incidence of 90 per
100,000 in the 6th decade, a lifetime cancer risk of 3.7%,
and a reproducible representation of type-speciﬁc HPV
within precancerous lesions and cervical cancer. A vaccine
that prevented 98% of persistent HPV 16/18 was asso-
ciated with an approximate equivalent reduction in
16/18-associated cancer and a 51% reduction in total cer-
vical cancer. A vaccine that prevented 75% of persistent
HPV 16/18 was associated with a 70% to 83% reduction
in 16/18-associated cancer cases. Several modeling
assumptions were identiﬁed that resulted in ampliﬁcation
or blunting of the vaccine’s effect on outcomes—however,
when the vaccine was either very ineffective (e.g., less
than 20% efﬁcacy) or very effective (e.g., more than 80%
efﬁcacy), the differences in projected outcomes associated
with these were minimal. CONCLUSIONS: A prophy-
lactic vaccine that prevents persistent HPV 16/18 
infection can be expected to signiﬁcantly reduce HPV-
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OBJECTIVES: It was hypothesised that the total cost of
managing a bleed in haemophilia patients with high titre,
high responding inhibitors (from initiation of the bleed to
resolution) by FEIBA or NovoSeven would be compara-
ble due to a higher ﬁrst-line efﬁcacy despite the greater
cost of NovoSeven. METHODS: Direct costs were 
compared from the perspective of the National Health
Service. Resource utilisation was based on a retrospective
analysis of bleeding episodes treated in Slovakia during
the period 1990–2001. Clinical outcomes were based on
a review of the international literature, data obtained
from the retrospective analysis and the consensus of an
expert panel of ﬁve Slovakian. A decision analytic eco-
